TY - JOUR
T1 - Inflammatory markers and cardiometabolic diseases
AU - Esser, N.
AU - Paquot, N.
AU - Scheen, A. J.
N1 - Publisher Copyright:
© Acta Clinica Belgica 2015.
PY - 2015/6
Y1 - 2015/6
N2 - Objectives: A growing body of evidence emerges that obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease are intimately related to chronic inflammation. Methods: A narrative review summarizing the most recent data of the literature describing the pathological implications of inflammation in obese patients with cardiometabolic disorders. Results: Besides high-sensitive C-reactive protein, various circulating or in situ inflammatory markers have been identified, presumably reflecting the presence of inflammation in various key-organs (visceral adipose tissue, skeletal muscle, pancreatic islets, liver, intestine, arterial wall). Available data support the concept that targeting inflammation, not only reduces systemic inflammatory markers, but also improves insulin sensitivity and ameliorates glucose control in insulin-resistant patients, thus potentially reducing the risk of cardiovascular complications. Conclusion: These observations confirm the role of inflammation in cardiometabolic diseases and support the development of pharmacological strategies that aim at reducing inflammation, especially in patients with type 2 diabetes.
AB - Objectives: A growing body of evidence emerges that obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease are intimately related to chronic inflammation. Methods: A narrative review summarizing the most recent data of the literature describing the pathological implications of inflammation in obese patients with cardiometabolic disorders. Results: Besides high-sensitive C-reactive protein, various circulating or in situ inflammatory markers have been identified, presumably reflecting the presence of inflammation in various key-organs (visceral adipose tissue, skeletal muscle, pancreatic islets, liver, intestine, arterial wall). Available data support the concept that targeting inflammation, not only reduces systemic inflammatory markers, but also improves insulin sensitivity and ameliorates glucose control in insulin-resistant patients, thus potentially reducing the risk of cardiovascular complications. Conclusion: These observations confirm the role of inflammation in cardiometabolic diseases and support the development of pharmacological strategies that aim at reducing inflammation, especially in patients with type 2 diabetes.
KW - C-reactive protein
KW - Cardiovascular disease
KW - Inflammation
KW - Insulin resistance
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84937640559&partnerID=8YFLogxK
U2 - 10.1179/2295333715Y.0000000004
DO - 10.1179/2295333715Y.0000000004
M3 - Article
C2 - 26103538
AN - SCOPUS:84937640559
SN - 1784-3286
VL - 70
SP - 193
EP - 199
JO - Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine
JF - Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine
IS - 3
ER -